Strategic initiatives focused on environment, sustainability and governance strategies might help pharmaceutical companies bring new therapies to market and meet patient-centric and financial benchmarks.
The fight against COVID-19 took another major step forward in early November of this year when the FDA officially approved vaccination against COVID-19 for children ages 5 to 11.
The AMA task forces released recommendations urging physicians to take
action to improve opioid prescribing practices, help prevent opioid use disorder, and provide evidence-based, compassionate care for patients in pain.
The FDA and the CDC this week announced that certain groups of people at high risk for serious COVID-19 infection can now get a booster dose of the Pfizer vaccine.
Individuals with substance use issues find it more challenging to get help due to limited access to facilities, widespread program cancellations and decreased prevention measures during the pandemic.